์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

Siladenoserinols A-L: new sulfonated serinol derivatives from a tunicate as inhibitors of p53-Hdm2 interaction.

Organic letters (2012-12-28)
Yuichi Nakamura, Hikaru Kato, Tadateru Nishikawa, Noriyuki Iwasaki, Yoshiaki Suwa, Henki Rotinsulu, Fije Losung, Wilmar Maarisit, Remy E P Mangindaan, Hiroshi Morioka, Hideyoshi Yokosawa, Sachiko Tsukamoto
์ดˆ๋ก

Siladenoserinols A-L were isolated from a tunicate as inhibitors of p53-Hdm2 interaction, a promising target for cancer chemotherapy. Their structures including the absolute configurations were elucidated to be new sulfonated serinol derivatives, each of which contains a 6,8-dioxabicyclo[3.2.1]octane unit and either glycerophosphocholine or glycerophosphoethanolamine moiety. They inhibited p53-Hdm2 interaction with IC(50) values of 2.0-55 ฮผM. Among them, siladenoserinol A and B exhibited the strongest inhibition with an IC(50) value of 2.0 ฮผM.

MATERIALS
์ œํ’ˆ ๋ฒˆํ˜ธ
๋ธŒ๋žœ๋“œ
์ œํ’ˆ ์„ค๋ช…

Sigma-Aldrich
Serinol, 98%